Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY21 results · Jan–Mar 2021
Aarti Drugs reported revenue from operations of ₹501.75 crore (up 11.6% from Q4 FY20) and net profit of ₹51.65 crore (down 12.2% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 501.75 | 449.64 | +11.6% | 530.25 | −5.4% |
| Other income | 0.97 | 0.99 | −2.0% | 2.00 | −51.5% |
| Total income | 502.72 | 450.63 | +11.6% | 532.25 | −5.5% |
| Profit before tax | 65.25 | 60.72 | +7.5% | 90.37 | −27.8% |
| Net profit for the period | 51.65 | 58.86 | −12.2% | 68.03 | −24.1% |
| EPS, basic (₹) | 5.54 | 25.26 | not comparable | 7.30 | −24.1% |
| Net margin (%) | 10.3 | 13.1 | 12.8 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 452.08 | 406.57 | +11.2% | 472.10 | −4.2% |
| Other income | 0.85 | 0.62 | +37.1% | 4.07 | −79.1% |
| Total income | 452.93 | 407.19 | +11.2% | 476.17 | −4.9% |
| Profit before tax | 63.24 | 57.36 | +10.3% | 85.16 | −25.7% |
| Net profit for the period | 50.24 | 56.56 | −11.2% | 64.66 | −22.3% |
| EPS, basic (₹) | 5.39 | 24.28 | not comparable | 6.94 | −22.3% |
| Net margin (%) | 11.1 | 13.9 | 13.7 |
Consolidated
- Filed with BSE
- 17 May 2021, 08:50 IST
- Board meeting
- 15 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2021, 08:50 IST
- Board meeting
- 15 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE